Pheochromocytoma in Dogs — Management Guide

Comprehensive, practical guide to diagnosis, pre-surgical stabilization (alpha‑blockade), adrenalectomy and long‑term care for canine pheochromocytoma.

Quick Overview

• What it is: Pheochromocytoma is a rare tumor of the adrenal medulla that secretes excessive catecholamines (epinephrine, norepinephrine), producing episodic signs such as tachycardia, hypertension and collapse.
• Who’s at risk: Typically older dogs (middle‑aged to geriatric), often medium‑to‑large breeds. Case series report over‑representation of German Shepherds, Labrador Retrievers, Boxers and Golden Retrievers. Overall prevalence is low; pheochromocytomas make up a minority of adrenal tumors.
• Prognosis: Highly variable. If detected early and surgically removed before vascular invasion or metastasis, dogs can have meaningful survival (often months to several years). Perioperative risk is significant; metastatic disease shortens survival.

Pathophysiology — explained simply

The adrenal gland has two main parts: the cortex (makes steroids) and the medulla (makes catecholamines). Pheochromocytomas arise from chromaffin cells of the adrenal medulla and release bursts of catecholamines. Those surges drive the clinical signs: rapid heart rate (tachycardia), high blood pressure (hypertension), abnormal heart rhythms, trembling, anxiety or sudden collapse. Tumors can be unilateral or bilateral, may invade local vessels (especially the caudal vena cava), and can metastasize to lymph nodes, lungs and liver.

Breed, age and prevalence notes

• Age: Most cases are diagnosed in middle‑aged to older dogs (commonly 8–12+ years).
• Breeds: Several retrospective series show overrepresentation of large breeds such as German Shepherds, Labrador Retrievers, Boxers and Golden Retrievers. However, any breed can be affected.
• Prevalence: Pheochromocytoma is uncommon. Among adrenal tumors, pheochromocytomas are less frequent than cortical (adenomas/adenocarcinomas) but represent an important diagnostic consideration because of their systemic effects.

Because secretion is often episodic, signs may come and go:

• Episodic signs (classic):

• Other signs:

Staging and severity

There is no single universally‑used clinical staging system. Practically dogs are categorized as:

• Localized, resectable: no vascular invasion or metastasis.
• Locally invasive: tumor invading the caudal vena cava or surrounding tissues — higher surgical risk.
• Metastatic: spread to lymph nodes, lungs, liver — surgical cure unlikely; management is palliative/adjunctive.

Goal: confirm catecholamine‑secreting tumor, locate it, and determine extent.

1) Baseline clinicopathologic tests

• CBC, biochemistry, urinalysis: may show stress leukogram, hyperglycemia, or proteinuria. These are nonspecific but important for anesthetic planning.

• Repeat noninvasive (doppler or oscillometric) or invasive arterial monitoring (for hospitalized patients). Hypertension can be intermittent — multiple readings at rest are useful.

• Urinary catecholamines and metanephrines (often reported as urine normetanephrine:creatinine ratio) or plasma free metanephrines: elevations support the diagnosis. In dogs, the urinary normetanephrine:creatinine ratio is commonly used because it is sensitive, though specificity varies and results must be interpreted with clinical and imaging findings.

• ECG for arrhythmias; echocardiography if heart disease suspected or arrhythmias are present.

• Abdominal ultrasound: first-line imaging to identify an adrenal mass, estimate size, and screen for local invasion. Operator‑dependant and may miss caval invasion.
• Contrast CT (thorax and abdomen): gold standard for surgical planning — better identifies invasion of the caudal vena cava, contralateral adrenal, and distant metastasis (thoracic CT for lungs).
• MRI: alternative for soft‑tissue definition, vascular invasion assessment.

• Referral to a veterinary internal medicine specialist and a board‑certified surgeon (ACVS) is recommended for adrenal mass cases, especially if surgery is contemplated.

Other adrenal tumors (cortical adenoma/adenocarcinoma), metastatic disease to the adrenal, and nonadrenal causes of episodic tachycardia/collapse (cardiac disease, hypoglycemia, seizure disorders).

Medical stabilization and pre‑surgical preparation

Perioperative complications are driven by catecholamine surges during tumor manipulation — careful preoperative stabilization reduces risk.

1) Alpha‑adrenergic blockade (essential)

• Purpose: prevent intraoperative hypertensive crises and reduce catecholamine effects.
• Common drugs:

• Duration: 7–14 days is common to allow vascular expansion and blood pressure stabilization. Some teams extend longer depending on clinical control.

• Controlled dietary salt increase and perioperative IV fluids help restore intravascular volume and reduce postrelease hypotension.

• If significant tachyarrhythmias persist after alpha blockade, a beta blocker can be added (e.g., propranolol 0.2–1 mg/kg PO TID or atenolol 0.5–1 mg/kg PO q12–24h). NEVER start a beta blocker before alpha blockade — unopposed alpha activity can worsen hypertension.

• Amlodipine (0.05–0.2 mg/kg PO q24h) or other antihypertensives can be used for persistent hypertension.
• Metyrosine (tyrosine hydroxylase inhibitor) reduces catecholamine synthesis; used rarely in veterinary patients for difficult cases (specialty drug, discuss with a specialist).

• Indication: surgical removal is the treatment of choice for resectable pheochromocytomas and offers the best chance for long‑term control or cure in nonmetastatic disease.
• Approach: open adrenalectomy is standard, with laparoscopic methods used selectively for small, noninvasive tumors. If the tumor invades the caudal vena cava, complex vascular surgery (including vascular reconstruction or patching) may be required and increases perioperative risk.
• Perioperative anesthetic considerations: continuous invasive blood pressure monitoring, readiness to treat hypertensive crises (short‑acting vasodilators such as nitroprusside, phentolamine) and hypotension after tumor removal (vasopressors, fluids). Experienced anesthesia and surgery teams lower complication rates.

• Perioperative mortality is influenced by tumor size, vessel invasion, and surgeon/anesthetist experience. Published series report perioperative mortality ranging widely (often cited in the veterinary literature as ~10–30% depending on case selection and center expertise).
• Long‑term survival: for dogs with completely resected, nonmetastatic pheochromocytoma, median survival times in retrospective studies commonly range from about 12 months to several years; some dogs survive multiple years. Dogs with vascular invasion or metastasis have shorter survival, and surgical cure is unlikely if metastasis is present.
• Data variability: because published case series are small and heterogeneous, individual prognosis depends on tumor behavior, surgical completeness, and presence of metastasis.

• Medical therapy (alpha blockers, antihypertensives) can control signs but does not cure the tumor.
• Chemotherapy has limited proven benefit for pheochromocytoma in dogs.
• Palliative radiation may be considered for local control in nonresectable cases on a case‑by‑case basis.
• Symptom‑directed care (control of hypertension, arrhythmias, and pain) can maintain quality of life.

• Recheck schedule after surgery for the first year commonly includes:

• Monitor for late cardiovascular complications and treat comorbidities.

• Quality of life after treatment can be very good if the tumor is localized and perioperative complications are avoided.
• Dogs with metastatic disease or significant vascular invasion may have progressive signs and shorter survival; palliative medical management can still provide months of good quality life in many cases.
• Decisions about surgery should weigh tumor stage, the dog’s overall health, the expertise of the surgical team, and the owner’s goals.

• Medication adherence: give alpha blockers/antihypertensives exactly as prescribed. Do not stop abruptly without veterinary guidance.
• Minimize stress: choose quiet, low‑stress walks and avoid situations that trigger excitement or fear, which can provoke catecholamine surges.
• Home monitoring: if available and trained, measure and record resting heart rate and note episodes of collapse or sudden lethargy. Bring a log to veterinary visits.
• Avoid certain medications: discuss all medications (including NSAIDs, over‑the‑counter drugs) with your vet — some drugs can affect blood pressure or heart rate.
• Diet and hydration: maintain normal sodium (do not restrict salt if alpha blockade is planned or ongoing unless advised by your vet) and ensure good hydration.
• Prepare for emergencies: know where to go for emergency veterinary care and have your surgeon’s contact details available around the time of surgery.

Seek immediate veterinary attention for:

• Recurrent or prolonged collapse or unconsciousness
• Persistent or very rapid heart rate (>160–180 bpm at rest) or fainting spells
• Seizure activity
• Sudden severe weakness, difficulty breathing or cyanosis
• Signs of significant bleeding or severe abdominal pain
• Any sudden change in behavior, appetite, or responsiveness

• Pheochromocytoma is a rare but important cause of episodic tachycardia, hypertension and collapse in dogs.
• Diagnosis is by clinical suspicion supported by urine/plasma metanephrine testing and confirmation/localization with imaging (ultrasound, contrast CT).
• Preoperative alpha blockade (phenoxybenzamine or prazosin) and volume optimization are essential to reduce intraoperative risk.
• Adrenalectomy offers the best chance for long‑term control or cure when the tumor is resectable; perioperative risk and prognosis vary with invasion and metastasis.
• Long‑term monitoring for recurrence and cardiovascular complications is necessary; with appropriate care, many dogs maintain meaningful quality of life.

References and further reading

• Merck Veterinary Manual — Pheochromocytoma in Animals. MerckVetManual.com
• ACVIM (American College of Veterinary Internal Medicine) textbook chapters and position statements on adrenal disease and perioperative management (consult ACVIM resources and your specialist)
• Veterinary surgery and internal medicine peer‑reviewed literature on adrenalectomy outcomes — discuss published survival data with your surgeon to understand center‑specific outcomes and risks.

Frequently Asked Questions